<DOC>
	<DOCNO>NCT00296465</DOCNO>
	<brief_summary>This study perform approximately 132 woman anovulatory/oligoovulatory infertility .</brief_summary>
	<brief_title>A Multicenter , Randomized , Double-Blind , Placebo-Controlled Study Assess Efficacy Safety Three Dosage Strengths Pulsatile GnRH</brief_title>
	<detailed_description>This multicenter , randomize , double-blind , placebo-controlled study perform approximately 132 woman anovulatory/oligoovulatory infertility . The treatment duration approximately 4 week pulsatile GnRH placebo 5 day Clomiphene Citrate placebo . All subject screen base inclusion/exclusion criterion , medical/infertility history general safety assessment . Subjects complete screen dispense 100 mg oral progesterone twice day 10 day induce uterine bleeding . On Cycle Day 5 start bleed subject randomly assign 1 7 treatment group . All subject monitor weekly throughout 4 week treatment period ovulation intercourse time . All subject require return study center total 8 visit . In addition , subject confirm clinical pregnancy monitor fetal heartbeat confirm approximately 5-6 week gestation</detailed_description>
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Prolactin Release-Inhibiting Factors</mesh_term>
	<mesh_term>Clomiphene</mesh_term>
	<mesh_term>Enclomiphene</mesh_term>
	<mesh_term>Zuclomiphene</mesh_term>
	<mesh_term>Citric Acid</mesh_term>
	<criteria>Inclusion Criteria 1 . Females age 18 ( 19 State Alabama ) 40 year . 2 . Infertile due ovulatory dysfunction describe : 3 . Positive progesterone withdrawal test follow screen visit . 4 . TSH ( thyroidstimulating hormone ) level within normal limit clinical laboratory consider clinically significant ( eg , secondary exogenous thyroid medication ) investigator 5 . Normal insulin sensitivity assess ratio fast blood glucose fast insulin &gt; 4.5 Screening 6 . Male partner recent ( within 6 month prior screen ) semen analysis show normalcy accord local laboratory normal criterion . If screening semen analysis borderline , couple accept study second sample obtain prior screen adequate . 7 . Presence ovary , without evidence clinically significant abnormality , detect transvaginal ultrasound 8 . Normal transvaginal ultrasound respect uterus adnexa ( eg , hydrosalpinx ) 9 . Hysterosalpingography hysteroscopy sonohysterogram document uterine cavity consistent expect normal function patency fallopian tube within previous 3 year prior screen ( within 1 year prior screen pelvic infection , endometriosis pelvic surgery ) . 10 . Negative serum pregnancy test ( qualitative ) prior progesterone test 11 . Desire become pregnant Exclusion Criteria 1 . Requires donor oocyte sperm 2 . Previous current use infertility modifier , include insulinsensitizing drug 3 . Primary amenorrhea/hypogonadotropic hypogonadism ( eg , isolated gonadotropin deficiency evidence primary/premature ovarian failure ) 4 . Presence clinically relevant systemic disease ( eg , diabetes mellitus , pituitary tumor , anorexia nervosa ) . 5 . Surgical medical condition judgment Investigator Sponsor may interfere absorption , distribution , metabolism , excretion drug use . 6 . Any pregnancy within last 3 month prior Screening . 7 . Patients body mass index ( BMI ) &gt; 30 time Screening 8 . Total testosterone DHEAS &gt; 1.5 time upper limit normal laboratory range prolactin &gt; 20 ng/mL 9 . Presence abnormal uterine bleeding undetermined origin . 10 . Active prior history substance abuse 11 . History chemotherapy ( except gestational condition ) radiotherapy 12 . Currently breast feeding , pregnant contraindication pregnancy 13 . Refusal inability comply requirement Protocol reason , include schedule clinic visit laboratory test . 14 . Documented intolerance allergy medication use include study medication 15 . Participation experimental drug study within 60 day prior Screening</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>May 2011</verification_date>
</DOC>